세계의 아브리스보 또는 아렉스비 시장 : 기회와 전략(-2034년)

The Abrysvo / Arexvy market refers to the segment of the immunization industry focused on vaccines designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV). This market encompasses the sales and administration of two leading RSV vaccines-Abrysvo, developed by Pfizer, and Arexvy, developed by GSK each targeting specific populations vulnerable to RSV infections.

The Abrysvo or Arexvy market consists of revenues generated by entities that are used in adults aged 60 years and older, pregnant individuals to confer infant protection, and adults aged 18-59 years who are at increased risk for severe RSV illness.

The global Abrysvo or Arexvy market reached a value of nearly $1,545.60 million in 2024, having declined at a compound annual growth rate (CAGR) of -39.36% since 2019. The market is expected to decline from $1,545.60 million in 2024 to $1,379.89 million in 2029 at a rate of -2.24%. The market is then expected to grow at a CAGR of 4.97% from 2029 and reach $1,758.34 million in 2034.

Supportive Government Health Policies

During the historic period, the abrysvo or arexvy market was driven by supportive government health policies. Policymakers and health authorities increasingly prioritized the prevention of respiratory syncytial virus (RSV) due to its substantial public health and economic burden, especially among infants and older adults. By integrating RSV vaccines into national immunization programs, governments aimed to strengthen population-level protection, reduce hospitalizations, and ease strain on healthcare systems. For instance, on February 2025, according to the Immunisation Coalition, an Australian not-for-profit organization, in the year 2024, Australia reported a record 175,786 RSV cases, the highest number ever recorded in the country. In response, the government announced the addition of Pfizer's Abrysvo to its National Immunization Program (NIP), beginning February 3, 2025, to protect infants via maternal vaccination during pregnancy. This move followed growing advocacy from medical experts and immunization coalitions highlighting RSV's impact on infants in their first six months of life. Such government-driven measures created a favorable regulatory and funding environment, directly accelerating the adoption of Abrysvo and Arexvy. Therefore, the abrysvo or arexvy market was mainly driven by supportive government health policies.

Global Prequalification Of Maternal Vaccines To Enhance Infant Immunization Coverage

Major companies in the vaccine market are focusing on maternal immunization strategies to protect infants during the first six months of life, a period of heightened vulnerability to respiratory syncytial virus (RSV). These innovations emphasize improving infant health outcomes, reducing hospitalization rates, and expanding global access to preventive solutions in both developed and low-resource settings. For instance, in March 2025, the World Health Organization (WHO) prequalified Abrysvo, a maternal RSV vaccine developed by Pfizer Inc., a US-based global pharmaceutical company specializing in innovative medicines and vaccines. Abrysvo is designed to provide protection to infants by transferring antibodies from mother to child during pregnancy, thereby reducing the risk of severe RSV-related illness in early infancy. By securing WHO prequalification, Pfizer aims to facilitate broader procurement through United Nations agencies, accelerate integration into national immunization programs, and expand access to life-saving RSV protection across global markets.

The global Abrysvo or Arexvy market is highly concentrated, with two large players operating in the market. The major 2 competitors in the market made up to 100% of the total market in 2024.

Abrysvo Or Arexvy Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global abrysvo or arexvy market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 11 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for abrysvo or arexvy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The abrysvo or arexvy market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider abrysvo or arexvy market; and compares it with other markets.

The report covers the following chapters

• Introduction And Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by clinical indication, by age group and by end user.
• Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
• Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
• Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by clinical indication, by age group and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
• Regional Market Size And Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
• Competitive Dashboard Briefs on competitive dashboard of major players.
• Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
• Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
• Recent Developments- Information on recent developments in the market covered in the report.
• Market Opportinities And Strategies - Contains information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
• Conclusions And Recommendations- This section includes recommendations for abrysvo or arexvy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention; Infant Protection
• 2) By Age Group: Adults (18-59 Years); Older Adults (60+ Years); Pregnant Individuals (32-36 Weeks Of Gestation)
• 3) By Distribution Channel: Hospitals And Healthcare Providers; Government / Public Health Programs; Other Distributional Channels
• Companies Mentioned: GlaxoSmithKline (GSK) Plc; Pfizer Inc.
• Countries: China; Australia; India; Japan; South Korea; USA; Canada; France; Germany; UK
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; abrysvo or arexvy indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Abrysvo Or Arexvy - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Abrysvo Or Arexvy Market Definition And Segmentations
• 6.4 Market Segmentation By Clinical Indication
  • 6.4.1 Respiratory Syncytial Virus (RSV) Prevention
  • 6.4.2 Infant Protection
• 6.5 Market Segmentation By Age Group
  • 6.5.1 Adults (18-59 Years)
  • 6.5.2 Older Adults (60+ Years)
  • 6.5.3 Pregnant Individuals (32-36 Weeks of Gestation)
• 6.6 Market Segmentation By Distribution Channel
  • 6.6.1 Hospitals And Healthcare Providers
  • 6.6.2 Government / Public Health Programs
  • 6.6.3 Other Distributional Channels

7 Major Market Trends

• 7.1 Global Prequalification Of Maternal Vaccines To Enhance Infant Immunization Coverage
• 7.2 Regulatory Expansion Of Adult RSV Vaccines To Broaden Protection Across Age Groups
• 7.3 Growing Adoption Of RSV Vaccines For High-Risk Adult Populations

8 Global Abrysvo Or Arexvy Growth Analysis And Strategic Analysis Framework

• 8.1 Global Abrysvo Or Arexvy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 8.1.1 Political
  • 8.1.2 Economic
  • 8.1.3 Social
  • 8.1.4 Technological
  • 8.1.5 Environmental
  • 8.1.6 Legal
• 8.2 Analysis Of End User (B2B) Market
  • 8.2.1 Healthcare Providers
  • 8.2.2 Pregnant Individuals
  • 8.2.3 High-Risk Adults
• 8.3 Global Abrysvo Or Arexvy Market Growth Rate Analysis
• 8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
  • 8.4.1 Market Drivers 2019 - 2024
  • 8.4.2 Market Restraints 2019 - 2024
• 8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
  • 8.5.1 Market Drivers 2024 - 2029
  • 8.5.2 Market Restraints 2024 - 2029
• 8.6 Global Abrysvo Or Arexvy Total Addressable Market (TAM)

9 Global Abrysvo Or Arexvy Market Segmentation

• 9.1 Global Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 9.2 Global Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 9.3 Global Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)

10 Abrysvo Or Arexvy Market, Regional and Country Analysis

• 10.1 Global Abrysvo Or Arexvy Market, By Region, Historic and Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 10.2 Global Abrysvo Or Arexvy Market, By Country, Historic and Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

• 11.1 Summary
• 11.2 Market Overview
  • 11.2.1 Region Information
  • 11.2.2 Market Information
  • 11.2.3 Background Information
  • 11.2.4 Government Initiatives
  • 11.2.5 Regulations
  • 11.2.6 Regulatory Bodies
  • 11.2.7 Major Associations
  • 11.2.8 Taxes Levied
  • 11.2.9 Corporate Tax Structure
  • 11.2.10 Investments
  • 11.2.11 Major Companies
• 11.3 Asia-Pacific Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.4 Asia-Pacific Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.5 Asia-Pacific Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.6 Asia-Pacific Abrysvo Or Arexvy Market: Country Analysis
• 11.7 China Market
• 11.8 Summary
• 11.9 Market Overview
  • 11.9.1 Country Information
  • 11.9.2 Market Information
  • 11.9.3 Background Information
  • 11.9.4 Government Initiatives
  • 11.9.5 Regulations
  • 11.9.6 Regulatory Bodies
  • 11.9.7 Major Associations
  • 11.9.8 Taxes Levied
  • 11.9.9 Corporate Tax Structure
  • 11.9.10 Investments
  • 11.9.11 Major Companies
• 11.10 China Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.11 China Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.12 China Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.13 India Market
• 11.14 India Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.15 India Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.16 India Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.17 Japan Market
• 11.18 Summary
• 11.19 Market Overview
  • 11.19.1 Country Information
  • 11.19.2 Market Information
  • 11.19.3 Background Information
  • 11.19.4 Government Initiatives
  • 11.19.5 Regulations
  • 11.19.6 Regulatory Bodies
  • 11.19.7 Major Associations
  • 11.19.8 Taxes Levied
  • 11.19.9 Corporate Tax Structure
  • 11.19.10 Investments
  • 11.19.11 Major Companies
• 11.20 Japan Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.21 Japan Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.22 Japan Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.23 South Korea Market
• 11.24 Summary
• 11.25 Market Overview
  • 11.25.1 Country Information
  • 11.25.2 Market Information
  • 11.25.3 Background Information
  • 11.25.4 Government Initiatives
  • 11.25.5 Regulations
  • 11.25.6 Regulatory Bodies
  • 11.25.7 Major Associations
  • 11.25.8 Taxes Levied
  • 11.25.9 Corporate Tax Structure
  • 11.25.10 Investments
  • 11.25.11 Major Companies
• 11.26 South Korea Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.27 South Korea Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.28 South Korea Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.29 Australia Market
• 11.30 Australia Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.31 Australia Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 11.32 Australia Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate tax structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Western Europe Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.4 Western Europe Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.5 Western Europe Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.6 Western Europe Abrysvo Or Arexvy Market: Country Analysis
• 12.7 UK Market
• 12.8 UK Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.9 UK Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.10 UK Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.11 Germany Market
• 12.12 Germany Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.13 Germany Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.14 Germany Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.15 France Market
• 12.16 France Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.17 France Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 12.18 France Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate Tax Structure
  • 13.2.10 Major companies
• 13.3 Eastern Europe Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 13.4 Eastern Europe Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 13.5 Eastern Europe Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Government Initiatives
  • 14.2.5 Regulations
  • 14.2.6 Regulatory Bodies
  • 14.2.7 Major Associations
  • 14.2.8 Taxes Levied
  • 14.2.9 Corporate Tax Structure
  • 14.2.10 Investments
  • 14.2.11 Major Companies
• 14.3 North America Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 14.4 North America Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 14.5 North America Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 14.6 North America Abrysvo Or Arexvy Market: Country Analysis
• 14.7 USA Market
• 14.8 Summary
• 14.9 Market Overview
  • 14.9.1 Country Information
  • 14.9.2 Market Information
  • 14.9.3 Background Information
  • 14.9.4 Government Initiatives
  • 14.9.5 Regulations
  • 14.9.6 Regulatory Bodies
  • 14.9.7 Major Associations
  • 14.9.8 Taxes Levied
  • 14.9.9 Corporate Tax Structure
  • 14.9.10 Investments
  • 14.9.11 Major Companies
• 14.10 USA Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 14.11 USA Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 14.12 USA Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 14.13 Canada Market
• 14.14 Summary
• 14.15 Market Overview
  • 14.15.1 Country Information
  • 14.15.2 Market Information
  • 14.15.3 Background Information
  • 14.15.4 Government Initiatives
  • 14.15.5 Regulations
  • 14.15.6 Regulatory Bodies
  • 14.15.7 Major Associations
  • 14.15.8 Taxes Levied
  • 14.15.9 Corporate Tax Structure
  • 14.15.10 Investments
  • 14.15.11 Major Companies
• 14.16 Canada Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 14.17 Canada Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 14.18 Canada Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Investments
  • 15.2.11 Major Companies
• 15.3 South America Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 15.4 South America Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 15.5 South America Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Major Companies
• 16.3 Middle East Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 16.4 Middle East Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 16.5 Middle East Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Major Companies
• 17.3 Africa Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 17.4 Africa Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
• 17.5 Africa Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

• 18.1 Company Profiles
• 18.2 Glaxo SmithKline (GSK) Plc
  • 18.2.1 Company Overview
  • 18.2.2 Products And Services
  • 18.2.3 Financial Overview
• 18.3 Pfizer Inc.
  • 18.3.1 Company Overview
  • 18.3.2 Products And Services
  • 18.3.3 Business Strategy
  • 18.3.4 Financial Overview

19 Competitive Benchmarking

20 Competitive Dashboard

21 Opportunities And Strategies

• 21.1 Global Abrysvo Or Arexvy Market In 2029 - Countries Offering Most New Opportunities
• 21.2 Global Abrysvo Or Arexvy Market In 2029 - Growth Strategies
  • 21.2.1 Market Trend Based Strategies
  • 21.2.2 Competitor Strategies

22 Abrysvo Or Arexvy Market, Conclusions And Recommendations

• 22.1 Conclusions
• 22.2 Recommendations
  • 22.2.1 Product
  • 22.2.2 Place
  • 22.2.3 Price
  • 22.2.4 Promotion
  • 22.2.5 People

23 Appendix

• 23.1 Geographies Covered
• 23.2 Market Data Sources
• 23.3 Research Methodology
• 23.4 Currencies
• 23.5 The Business Research Company
• 23.6 Copyright and Disclaimer